<DOC>
	<DOCNO>NCT01609881</DOCNO>
	<brief_summary>Objective research study : 1 . To measure anterior chamber vitreous ketorolac ( Acuvail® ) concentration topical administration patient undergo routine vitrectomy determine ability medication penetrate anterior chamber vitreous cavity , compare level IC50 cyclooxygenase-1 -2 enzyme ( COX-1 COX-2 ) 2 . To measure vitreous concentration prostaglandin subtypes ( PGE , PGD , PGF ) inflammatory mediator ( Interleukin-1β [ IL-1β ] , IL-6 , IL-8 , tumor necrosis factor [ TNF ] -α , VEGF ) diabetic nondiabetic patient undergo vitrectomy 3 . To determine topical ketorolac ( Acuvail® ) penetrate anterior chamber vitreous cavity sufficiently decrease level intraocular inflammatory mediator show elevated diabetic patient 4 . To serve precursor 5-year longitudinal clinical trial determine chronically administer topical ketorolac ( Acuvail® ) prevent , delay slow diabetic retinopathy . Research hypothesis 1 . Ketorolac ( Acuvail® ) penetrate anterior chamber vitreous cavity sufficiently achieve level IC50 COX-1 COX-2 2 . Prostaglandin inflammatory mediator level anterior chamber vitreous cavity significantly high among diabetic patient nondiabetic control 3 . Acuvail® significantly low anterior chamber vitreous cavity level prostaglandins inflammatory mediator diabetic patient</brief_summary>
	<brief_title>The Role Prostaglandins Progression Diabetic Retinopathy</brief_title>
	<detailed_description>Patients require vitrectomy indication meeting inclusion/exclusion criterion include . Patients consent participate study surgery . Nondiabetic patient include one two group . Twenty receive topical ketorolac ( Acuvail® ) preoperatively 3 day sample take time surgery . Twenty patient serve control intraocular prostaglandin cytokine level ( compare diabetic patient ) . This group receive preoperative ketorolac ( Acuvail® ) . Diabetic patient include one two group . Twenty patient intraocular prostaglandin cytokine level measure . Twenty patient interventional group determine topical ketorolac ( Acuvail® ) successfully low intraocular prostaglandin inflammatory cytokine level . In case , patient undergo vitreoretinal surgery surgical treatment choice condition . For study , undiluted sample draw vitreous cavity anterior chamber begin vitrectomy . These sample store , analyze frozen . Samples test prostaglandin level , addition inflammatory cytokine , ketorolac level . Three day Acuvail® give four time per day choose , previous study show one dose ketorolac 0.4 % achieves peak aqueous concentration 57.5 ng/mL,1 12 dos two day achieve aqueous concentration 1079 ng/mL.2 Both value well IC50 COX-1 ( 5.3 7.5 ng/mL ) COX-2 ( 33.9-45.2 ng/mL ) . The upper end dose spectrum chosen , dose long duration therapy likely required achieve sufficient vitreous level inhibit COX-1 COX-2 . This dose regimen also use another clinical study assess ketorolac level prostaglandin level vitreous cavity topical administration four time day three day preoperatively.3</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<criteria>1 . Adult patient age 18 year old present vitrectomy surgery indication . 2 . Diabetic nondiabetic patient include . Exclusion criterion : 1 . Patients age 18 year age . 2 . Pregnant woman . 3 . Patients history vitrectomy surgery . 4 . Current topical , periocular , intraocular systemic corticosteroid use 5 . Coexistent macular , retinovascular ocular inflammatory disease ( agerelated macular degeneration , retinal venous occlusive disease , uveitis , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Inflammation</keyword>
</DOC>